ClinicalTrials.gg
CompletedNCT03353675Updated Jan 11, 2022Results posted

A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of TG4010 and Chemotherapy in Non Small Cell Lung Cancer Metastatic, sponsored by Transgene. Completed at 9 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Transgene · Phase 2, Interventional, and Treatment

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 874 studies in Carcinoma, Non-Small-Cell Lung with a site in France — 169 open to participants now, 327 under way, 106 of them phase 3. Carcinoma, Non-Small-Cell Lung · France.

Enrollment
649th of 761
44 · median 190
Started
2018
with 39 others
Phase 2
243 of 874
27 open now
Registered
392nd of 874
by date

Among the 874 studies in Carcinoma, Non-Small-Cell Lung with a site in France, this one is the 649th largest by enrollment of the 761 interventional ones that give a count, is one of 40 that started in 2018, is one of 243 in phase 2, and was the 392nd registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

169 of the 874 studies in Carcinoma, Non-Small-Cell Lung with a site in France are open now. Recruiting first, the newest first:

164 more — sign in →

All 169 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 874 studies in Carcinoma, Non-Small-Cell Lung with a site in France, or all of them as a file.
02

Study summary

This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and with \< 50% of tumor cells expressing programmed death-ligand 1 (PD-L1) by immunohistochemical (IHC) staining.

03

Conditions studied

  • Non Small Cell Lung Cancer Metastatic

Keywords

  • Metastatic NSCLC
  • Advanced lung malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Principal Inclusion Criteria:

  • Female or male patients age > 18 years-old
  • (ECOG) performance status (PS) 0 or 1 at study entry
  • of at least 3 months
  • confirmed non-squamous NSCLC (adenocarcinoma, large cell carcinoma, undifferentiated carcinoma or other)
  • Stage IIIB-IV cancer or delayed relapse of any stage not amenable to surgery or radiotherapy with curative intent.
  • expression by immunohistochemistry in \< 50% of tumor cells
  • Patients must be chemotherapy-naïve for the advanced stage of the disease. Previous and/or adjuvant chemotherapy is allowed for patients who successfully underwent complete radical surgery and if last treatment was administered more than 12 months prior to the start of the study treatment.
  • At least one by CT scan based on 1.1 performed within 28 days prior to start of study treatment
  • Adequate hematological, hepatic, and renal functions
  • Women of (WOCBP) must have a negative serum pregnancy test within 72 hours prior to the start of study drug
  • WOCBP must agree to follow instructions for method(s) of for the duration of treatment with study drug(s) plus 5 half-lives of study drug plus 30 days for a total of 5 months posttreatment completion. Highly effective contraception are defined in the protocol.
  • Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 90 days for a total of 7 months post-treatment completion

Principal Exclusion Criteria:

  • Patients having central nervous system (CNS)
  • Patients with pericardial effusion
  • Prior exposure to cancer immunotherapy including cancer vaccines, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-Lymphocyte antigen- 4 antibody or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
  • Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)- rearrangements leading to eligibility for tyrosine kinase inhibitor (TKI) treatment (tests mandatory)
  • Prior history of other except basal cell carcinoma of the skin, cervical intra epithelial neoplasia, and other cancer curatively treated with no evidence of disease for at least 3 years
  • Patients with a condition requiring systemic treatment with either or other medications within 14 days of start of study treatment
  • Patients with an active, known or suspected disease
  • Patient with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
  • Patients with grade ≥ 2 neuropathy
  • Signs or symptoms of infection within 14 days prior to start of study treatment or active infection requiring systemic therapy
  • Positive serology for or virus (HCV); presence in the serum of the antigens (HBs) at baseline
  • Patient with any underlying medical condition that the treating physician considers might be aggravated by treatment or which is not controlled (e.g., elevated troponin or creatinine, uncontrolled diabetes)
  • History of cardiovascular conditions within 12 months of enrollment
  • less than the Lower Limit of Normal as assessed by echocardiography (or multigated acquisition (MUGA) scan)
  • Patient with major surgery or radiotherapy within 3 weeks prior to the start of the study treatment. However, prior surgery or radiation therapy aimed at local palliation or attempted local disease control (except in case of thoracic radiotherapy) is permitted but has to be completed 2 weeks before treatment start
  • Pregnant or nursing (lactating) women
  • Patients with an organ allograft
  • Any known allergy to eggs, gentamicin or history of allergy or to study drug components
  • Participation in a clinical study with an product within 4 weeks prior to the start of the study treatments
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    TG4010/Chemotherapy/Nivolumab

    Biological: TG4010 · Drug: Chemotherapy · Drug: Nivolumab

Interventions

  • BiologicalTG4010

    1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks

  • DrugChemotherapy

    Pemetrexed/Cisplatin or Carboplatin Pemetrexed maintenance

  • 360 mg IV administration every 3 weeks

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Percentage of participants whose best overall response is complete response or partial response using RECIST 1.1. confirmed by a second scan no less than 4 weeks after the criteria for response are first met. Complete response: disappearance of all lesions and no new lesions. Partial response: decrease of at least 30% in the sum of the diameters of measurable lesions taking as reference the baseline sum of diameters, no progression of non-measurable lesions and no new lesions.

    Time frame: 15 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time from the date of the first study drug administration to the date of first documented tumor progression or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The Kaplan-Meier estimator was used to estimate median PFS and its confidence interval.

    Time frame: 28 months

  2. Disease Control Rate (DCR)

    Percentage of participants whose best overall response is either complete response, partial response or stable disease. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scan or MRI: Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions and no measurable non-target lesions; Stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD).

    Time frame: 15 months

  3. Overall Survival

    Overall Survival (OS) is defined as the time from the first study drug administration to the date of death due to any cause. The Kaplan-Meier estimator was used to estimate median OS and its confidence interval.

    Time frame: 28 months

  4. Duration of Overall Response (DoR)

    Time from first documented response (complete response or partial response) until documented disease progression or death due to lung cancer.

    Time frame: 28 months

  5. Number of Participants With Adverse Events or Abnormalities

    The assessment of safety of the combination was based mainly on the frequency of adverse events, serious adverse events, adverse events of special interest (Injection site reaction, fatigue, pyrexia, infusion-related reactions and diarrhea), immune-mediated adverse events and laboratories abnormalities.

    Time frame: 28 months

07

Results

Posted Jan 11, 2022

Participant flow

The study was conducted at 2 study sites in United States, 4 sites in France, 2 sites in Hungary and 1 site in Belgium.

Participant flow — Overall Study
MilestoneTG4010/Chemotherapy/Nivolumab
Started44
Completed40
Not completed4
Withdrew: Adverse event4

Outcome measures

PrimaryObjective Response Rate (ORR)

Percentage of participants whose best overall response is complete response or partial response using RECIST 1.1. confirmed by a second scan no less than 4 weeks after the criteria for response are first met. Complete response: disappearance of all lesions and no new lesions. Partial response: decrease of at least 30% in the sum of the diameters of measurable lesions taking as reference the baseline sum of diameters, no progression of non-measurable lesions and no new lesions.

Time frame:
15 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsTG4010/Chemotherapy/Nivolumab
Objective Response Rate (ORR)32.5 (20.4 to 46.6)
SecondaryProgression Free Survival (PFS)

Time from the date of the first study drug administration to the date of first documented tumor progression or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The Kaplan-Meier estimator was used to estimate median PFS and its confidence interval.

Time frame:
28 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsTG4010/Chemotherapy/Nivolumab
Progression Free Survival (PFS)5.7 (1.5 to 11.1)
SecondaryDisease Control Rate (DCR)

Percentage of participants whose best overall response is either complete response, partial response or stable disease. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scan or MRI: Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions and no measurable non-target lesions; Stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD).

Time frame:
15 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsTG4010/Chemotherapy/Nivolumab
Disease Control Rate (DCR)75.0 (61.3 to 85.8)
SecondaryOverall Survival

Overall Survival (OS) is defined as the time from the first study drug administration to the date of death due to any cause. The Kaplan-Meier estimator was used to estimate median OS and its confidence interval.

Time frame:
28 months
Reported as:
Median · Months
Overall Survival
MonthsTG4010/Chemotherapy/Nivolumab
Overall Survival14.9 (8.0 to NA)
SecondaryDuration of Overall Response (DoR)

Time from first documented response (complete response or partial response) until documented disease progression or death due to lung cancer.

Time frame:
28 months
Reported as:
Median · Weeks
Duration of Overall Response (DoR)
WeeksTG4010/Chemotherapy/Nivolumab
Duration of Overall Response (DoR)74.9 (19.4 to 92.6)
SecondaryNumber of Participants With Adverse Events or Abnormalities

The assessment of safety of the combination was based mainly on the frequency of adverse events, serious adverse events, adverse events of special interest (Injection site reaction, fatigue, pyrexia, infusion-related reactions and diarrhea), immune-mediated adverse events and laboratories abnormalities.

Time frame:
28 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events or Abnormalities
ParticipantsTG4010/Chemotherapy/Nivolumab
Adverse events44
Serious adverse events28
Adverse events of special interest37
Immune-mediated adverse events14
Grade 3/4 laboratories abnormalities31

Adverse events

Collected over Collection of adverse events / serious adverse events starts from the date of signature of the informed consent form up to the safety follow-up visits (100 days after the last administration of any study treatment administration). Timeframe was approximately 28 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TG4010/Chemotherapy/Nivolumab28/44 (63.6%)28/44 (63.6%)43/44 (97.7%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventTG4010/Chemotherapy/Nivolumab
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders9/44
VOMITINGGastrointestinal disorders3/44
FEBRILE NEUTROPENIABlood and lymphatic system disorders2/44
FATIGUEGeneral disorders2/44
PNEUMONIAInfections and infestations2/44
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders2/44
DEEP VEIN THROMBOSISVascular disorders2/44
THROMBOCYTOPENIABlood and lymphatic system disorders1/44
ABDOMINAL PAINGastrointestinal disorders1/44
AUTOIMMUNE COLITISGastrointestinal disorders1/44
Most frequent other events
Showing 10 of 46
Most frequent other events
EventTG4010/Chemotherapy/Nivolumab
FATIGUEGeneral disorders29/44
NAUSEAGastrointestinal disorders26/44
ANAEMIABlood and lymphatic system disorders24/44
DIARRHOEAGastrointestinal disorders17/44
CONSTIPATIONGastrointestinal disorders16/44
NEUTROPENIABlood and lymphatic system disorders14/44
THROMBOCYTOPENIABlood and lymphatic system disorders13/44
DECREASED APPETITEMetabolism and nutrition disorders13/44
DYSPNOEARespiratory, thoracic and mediastinal disorders13/44
COUGHRespiratory, thoracic and mediastinal disorders12/44

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TG4010/Chemotherapy/Nivolumab
<=18 years0
Between 18 and 65 years28
>=65 years16
Age, Continuous
Age, Continuous(years)TG4010/Chemotherapy/Nivolumab
Mean61.7 ± 8.64
Sex: Female, Male
Sex: Female, Male(Participants)TG4010/Chemotherapy/Nivolumab
Female17
Male27
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)TG4010/Chemotherapy/Nivolumab
Region of Enrollment
Region of Enrollment(participants)TG4010/Chemotherapy/Nivolumab
Belgium6
Hungary6
United States6
France26
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(participants)TG4010/Chemotherapy/Nivolumab
ECOG PS 021
ECOG PS 123
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)TG4010/Chemotherapy/Nivolumab
Median24.4 (15 to 37)
PD-L1 percentage of stained cells
PD-L1 percentage of stained cells(Participants)TG4010/Chemotherapy/Nivolumab
<122
1 - <5022
≥500
08

Study locations

9 sites
  • Charlotte
    Charlotte, North Carolina 28204, United States
  • Nashville
    Nashville, Tennessee 37203, United States
  • Libramont
    Libramont, Belgium
  • Créteil
    Créteil, France
  • Mulhouse
    Mulhouse, France
  • Rennes
    Rennes, France
  • Strasbourg
    Strasbourg, France
  • Budapest
    Budapest, Hungary
  • Szekesfehervar
    Szekesfehervar, Hungary
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Nov 2019, 22 months.

Results were first posted in Jan 2022, 2 years 1 month after primary completion. A results delay was requested in Aug 2020.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2017
First posted
Nov 27, 2017
StartActual
Jan 5, 2018
Primary completionActual
Nov 20, 2019
CompletionActual
Feb 17, 2021
Results delay requested
Aug 19, 2020
Results first posted
Jan 11, 2022
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03353675
Lead sponsor
Transgene
Responsible party
Sponsor
First posted
Nov 27, 2017
Start date
Jan 5, 2018
Primary completion
Nov 20, 2019
Completion
Feb 17, 2021
Results posted
Jan 11, 2022
Last update
Jan 11, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG4010

Start the discussion